Urinary Catheter Management and Treatment of Urinary Retention

Introduction to Urinary Catheter Management

• Remove indwelling catheter as soon as the patient is medically and neurologically stable, and initiate intermittent catheterization if needed, with the goal of preventing filling of the bladder beyond 500 mL, according to the American Heart Association 1
• Remove indwelling catheters within 48 hours when possible to reduce the risk of urinary tract infections (UTIs), as recommended by the American Heart Association 1

Bladder Training and Assessment

• Implement a bladder-training program with toileting every 2 hours during waking hours and every 4 hours at night to help patients with urinary incontinence or retention, as recommended by the American Heart Association 1
• Assess for urinary retention through repeated bladder scans or intermittent catheterizations, especially in stroke patients with incontinence or retention, according to the American Stroke Association 2
• Perform bladder scans to assess retention upon admission in stroke patients with incontinence or retention, and continue monitoring according to the 4-6 hour schedule 2

Prevention of Urinary Tract Infections

• Immediate bladder decompression via catheterization is essential for acute urinary retention, with options including urethral catheterization as the first-line approach and suprapubic catheterization if the urethral approach fails or is contraindicated, as recommended by urological guidelines 3
• The American Heart Association recommends keeping the catheter in place for at least 48-72 hours to allow urethral healing 1
• The Infectious Diseases Society of America suggests considering prophylactic antibiotics only if high risk for infection (not routinely recommended) 4

Medical Management of Urinary Retention

• Alpha blockers, such as tamsulosin (0.4 mg daily) or alfuzosin (10 mg daily), are recommended as initial medications for urinary retention, with a strength of evidence rated as high 3, 5, 6
• 5-alpha reductase inhibitors (5-ARIs), such as finasteride or dutasteride, can reduce the risk of acute urinary retention by 67% compared to placebo, and the risk of BPH-related surgery by 64%, with a strength of evidence rated as high 5, 3, 6
• Combination therapy with an alpha blocker and 5-ARI can reduce the risk of urinary retention by 67% compared to 34% with finasteride alone and 39% with doxazosin alone, as recommended by the American Urological Association 7
• Beta-3 agonists, such as mirabegron, can be used in combination with alpha blockers for patients with persistent storage symptoms, with a low risk of worsening urinary retention (1.7% incidence of AUR) 5, 6
• Avoid prescribing anticholinergic medications for overactive bladder symptoms in patients with retention, as these can worsen retention, according to the American Urological Association 8

Surgical Management of Urinary Retention

• Surgical options are indicated for patients who fail medical management, have refractory retention, or develop complications such as renal insufficiency, recurrent UTIs, hematuria, or bladder stones, with TURP being the most common and effective option, according to surgical guidelines 3
• Urethroplasty is an option for patients with urethral strictures, with a 90-95% long-term success rate, although the specific citation for this success rate is not provided, it is a recognized treatment approach in urology 3
• Transurethral resection of the prostate (TURP) is an effective option to free patients from long-term catheterization for BPH-related retention, and should be considered for patients who fail medical management or have severe symptoms, as recommended by the American Urological Association 5, 7

Monitoring and Follow-up

• Treatment success should be assessed after 2-4 weeks of alpha-blocker therapy, using measures such as post-void residual volume and validated questionnaires (IPSS) to track improvement, as suggested by the European Association of Urology 9
• Patients should be monitored for orthostatic hypotension, especially with the first dose of alpha blockers, and advised about possible side effects, including dizziness, headache, and ejaculatory dysfunction, according to the American Urological Association 3
• Measure post-void residual (PVR) volume through bladder scanning or intermittent catheterization to assess urinary retention, particularly in patients with a history of urological issues or cognitive awareness of need to void, as recommended by the American Urological Association 10, 11
• Significant retention is defined as PVR volume >100 mL measured consecutively three times 10

Treatment Options Summary

Causes of Urinary Retention

• Urinary retention can be caused by medications with anticholinergic properties, such as tricyclic antidepressants and gabapentin, according to the American Society of Clinical Oncology 12
• When a patient presents with urinary retention, it is essential to rule out other causes, especially spinal cord compression in patients with cancer or neurological conditions, as recommended by the American Society of Clinical Oncology 12